论文部分内容阅读
[目的]:探讨硫普罗宁联合拉米夫定在肺结核合并慢性乙型肝炎患者治疗中的应用效果分析。[方法]选取我院2012年1月~2016年1月收治的90例肺结核合并慢性乙型肝炎患者作为本研究对象,按随机数字表的方法分为3组,包括药物联合组(n=30)、拉米夫定组(n=30)和对照组(n=30),对照组患者接受2 HRZE/4 HR+常规保肝药+维生素C进行治疗,拉米夫定患者组在对照组基础上使用拉米夫定药物进行治疗,药物联合组患者则在拉米夫定的基础上加以使用硫普罗宁药物进行治疗。分别对3组患者的临床症状持续时间、肝功能情况以及血清纤维化指标进行客观的评定和比较。[结果]3组患者经治疗后比较,药物联合组的发热消退时间、咳嗽停止时间、盗汗消退时间等明显更短于其他2组,其中,对照组患者的症状时间最长(P<0.05);3组患者治疗后的ALT、AST、TBIL水平明显下降,低于治疗前,且3组间的ALT、AST、TBIL水平比较有统计学意义,其中药物联合组改善的最为显著(P<0.05);同时,治疗后药物联合组和拉米夫定组患者的各血清纤维化指标(PCIII、IV-C、HA)明显降低(P<0.05),明显更低于对照组,其中药物联合组最低。[结论]硫普罗宁联合拉米夫定治疗肺结核合并慢性乙型肝炎患者可以有效改善患者的不良症状的同时保护肝功能,可以辅助促进短程化疗的疗效,值得推广应用。
[Objective] To investigate the effect of tiopronin combined with lamivudine in the treatment of patients with pulmonary tuberculosis and chronic hepatitis B. [Methods] Ninety patients with tuberculosis combined with chronic hepatitis B who were admitted to our hospital from January 2012 to January 2016 were selected as the subjects and divided into 3 groups according to random number table (n = 30) ), Lamivudine group (n = 30) and control group (n = 30). The control group received 2 HRZE / 4 HR + conventional hepatoprotective drugs plus vitamin C. The patients in lamivudine group were treated on the basis of control group On the use of lamivudine drug treatment, the drug combination group patients were treated with tiopronin on the basis of lamivudine. The duration of clinical symptoms, liver function and serum fibrosis indexes of three groups were evaluated and compared objectively. [Result] Compared with the other two groups, the fever subsidence time, cough stop time and night sweats disappearance time were significantly shorter in the three groups after treatment. Among them, the symptoms of the control group were the longest (P <0.05) ; The levels of ALT, AST and TBIL in three groups after treatment were significantly lower than those before treatment, and the levels of ALT, AST and TBIL in the three groups were statistically significant (P <0.05 ); Meanwhile, the serum fibrosis indexes (PCIII, IV-C, HA) in the drug combination group and the lamivudine group were significantly lower (P <0.05) after treatment, which were significantly lower than those in the control group lowest. [Conclusion] The combination of tiopronin and lamivudine in the treatment of patients with pulmonary tuberculosis and chronic hepatitis B can effectively improve the patients’ adverse symptoms and protect the liver function, and can be used to promote the curative effect of short-course chemotherapy, which is worth popularizing and applying.